tirzepatide vs semaglutide benefits caused roughly half as many patients to stop treatment because of gastrointestinal side effects as semaglutide. In the first major head-to-head obesity trial, GI side effects caused treatment discontinuation in: Tirzepatide Semaglutide vs. Tirzepatide for Weight

We dont prevent, treat or cure any diseases

Early data show that people lose between 10 and 15 percent of their body weight after 36 weeks on the drug

Overall, many patients in both groups explored other weight-management treatment options within 12 months of stopping their initial GLP-1 injectable: Researchers say the findings underscore the importance of personalized, ongoing support for patients seeking obesity treatment even when they stop medication

NICE guidance (NG28 for type 2 diabetes, TA875 for semaglutide 2.4 mg, and TA664 for liraglutide 3 mg) recommends regular monitoring of patients on GLP-1 therapy, with particular attention to tolerability and adverse effects